Last updated: February 24, 2026
What Is the Product Associated with NDC 00002-8233?
NDC 00002-8233 corresponds to Humira (adalimumab), a monoclonal antibody developed by AbbVie. It is approved for multiple indications including rheumatoid arthritis, Crohn’s disease, psoriasis, and other autoimmune conditions. Humira remains one of the best-selling drugs globally, with significant revenue generation for AbbVie.
Market Size and Trends
Current Market Landscape
Humira's revenue peaked at approximately $20.4 billion in 2021 (IQVIA, 2022). It maintained dominant market share in biologic treatments for autoimmune diseases until recent biosimilar entries.
Competition and Biosimilars
In 2023, biosimilars of Humira launched across multiple markets, aiming to capture a significant portion of the market share. Notable biosimilars include:
- Amjevita (Amgen/AbbVie partnership)
- Cyltezo (Boehringer Ingelheim)
- Hyrimoz (Sandoz)
The entry of biosimilars has driven pricing pressure and market share redistribution.
Global Market Value
The global biologics market for autoimmune diseases was valued at approximately $150 billion in 2022 and is projected to reach $250 billion by 2030 (Grandview Research, 2023). Biologics' share of this market is increasing as more biosimilars enter the space.
Regional Variations
- United States: Largest market with high pricing, facing biosimilar erosion.
- Europe: Active biosimilar adoption, with cost-driven pricing.
- Emerging Markets: Growing access but limited affordability, with continued reliance on originator products.
Price Trends and Projections
Historical Pricing Patterns
- United States: List price of Humira in 2022 was approximately $6,000 per month per patient.
- European Markets: Prices ranged from €1,150 to €1,500 per month, reflecting national negotiation differences.
- Biosimilars: Entry in 2023 reduced list prices by an average of 30-50%, with some states in the U.S. reporting discounts up to 70%.
Near-term Price Projections (2023-2025)
| Year |
US List Price (per month) |
European Average Price (per month) |
Notes |
| 2023 |
$6,000 |
€1,150 |
Bioskims introduced in US |
| 2024 |
$5,400 (10% decline) |
€1,030 (-10%) |
Discount effects stabilize |
| 2025 |
$4,860 (-10%) |
€920 (-10%) |
Continued biosimilar penetration |
Long-term Price Outlook (2026-2030)
- United States: List prices may decline further to around $3,600-$4,000 per month as biosimilar market shares increase.
- Europe: Prices could reach €700-€900 due to aggressive biosimilar competition.
- Global: Price variations will persist, influenced by local healthcare policies and market acceptance.
Factors Influencing Future Pricing
- Patent expiry: The expiration of Humira's U.S. patents occurred in 2023, facilitating biosimilar competition.
- Market share shifts: Biosimilar adoption in the U.S. and Europe could reduce the revenue contribution from Humira.
- Regulatory landscape: Policies favoring biosimilar use and price negotiations directly impact pricing.
- Manufacturing costs: Remain relatively stable but influence margins more than list prices.
Revenue and Volume Trends
Anticipated biosimilar erosion is likely to lead to:
- Decreased revenue per patient
- Increased patient access due to lower prices
- Shifts from originator to biosimilar products
In the U.S., Humira sales are projected to decline by 30-50% by 2025, with total revenue dropping proportionally.
Market Entry and Strategic Movements
- AbbVie has introduced a self-developed biosimilar (Amjevita) to retain some revenue streams.
- Some regions are implementing tender-based pricing, driving discounts.
- Companies are exploring new indications and delivery modes (e.g., subcutaneous devices) to sustain market share.
Key Considerations for Stakeholders
- Potential for pricing to stabilize by 2026, marking a new equilibrium.
- The rise of biosimilar competition makes cost containment a primary focus for healthcare providers and payers.
- Ongoing regulatory updates and market dynamics will shape long-term pricing strategies.
Key Takeaways
- Humira's revenue has experienced significant decline post-patent expiry due to biosimilar competition.
- US list prices have decreased approximately 10-15% annually since biosimilar launch.
- Long-term prices are projected to stabilize between $3,600 and $4,000 per month in the US by 2026.
- Global pricing varies widely, with emerging markets seeing continued reliance on originators but increased biosimilar adoption.
- The market will remain highly competitive, with future growth driven more by volume and expanded indications than by pricing.
FAQs
1. When did biosimilars for Humira begin to launch in the US?
Biosimilars launched in the US in January 2023, following patent expiry.
2. How much have biosimilar prices reduced compared to Humira?
In the US, biosimilar prices are approximately 30-50% lower than the originator, with discounts up to 70% in some cases.
3. Will Humira regain market share despite biosimilar competition?
Limited; biosimilar entry significantly eroded Humira’s market share, with further decreases expected through 2025.
4. What indications are most affected by price reductions?
Primarily autoimmune indications like rheumatoid arthritis, psoriasis, and Crohn’s disease.
5. Are new formulations or indications expected to sustain Humira’s revenue?
Yes, ongoing development of new indications and formulations may help preserve revenue streams, but biosimilars remain a major factor.
References
[1] IQVIA. (2022). Biologic medicine market report.
[2] Grandview Research. (2023). Biologics market size, share & trend analysis.
